Compare EDD & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDD | ATYR |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.7M | 49.2M |
| IPO Year | N/A | 2015 |
| Metric | EDD | ATYR |
|---|---|---|
| Price | $5.24 | $0.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $2.86 |
| AVG Volume (30 Days) | 305.8K | ★ 2.7M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.96 | $0.27 |
| 52 Week High | $6.18 | $1.12 |
| Indicator | EDD | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 30.47 | 26.30 |
| Support Level | $4.96 | N/A |
| Resistance Level | $5.66 | $0.59 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 18.57 | 17.58 |
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).